Episode 63. Management of Follicular Lymphoma with Dr. Gilles Salles

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/ec/ff/29/ecff295f-8f4c-e8f2-8d5c-0c8a88cb945e/mza_11191508321578000071.jpg/600x600bb.jpg

Blood Cancer Talks

Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

67 episodes

1 month ago

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

All content for Blood Cancer Talks is the property of Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Education

Health & Fitness,

Medicine

Episode 63. Management of Follicular Lymphoma with Dr. Gilles Salles

Blood Cancer Talks

51 minutes

3 months ago

Episode 63. Management of Follicular Lymphoma with Dr. Gilles Salles

In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed:

1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/

2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/

3. Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma: https://pubmed.ncbi.nlm.nih.gov/40306831/

4. RELEVANCE RCT: Lenalidomide plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.22.00843

5. GALLIUM RCT: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL. https://pubmed.ncbi.nlm.nih.gov/37404773/

https://pubmed.ncbi.nlm.nih.gov/28976863/

6. Long-term follow-up of mosunetuzumab in relapsed/refractory FL:

https://pubmed.ncbi.nlm.nih.gov/39447094/

7. Epcoritamab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/38889737/

8. Phase 3 inMIND RCT: Tafasitamab plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: https://ashpublications.org/blood/article/144/Supplement%202/LBA-1/534319

9. Long term follow-up results from the Phase 3 PRIMA trial of rituximab maintenance in Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.19.01073